1. Home
  2. MLYS vs RGR Comparison

MLYS vs RGR Comparison

Compare MLYS & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$37.58

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Logo Sturm Ruger & Company Inc.

RGR

Sturm Ruger & Company Inc.

HOLD

Current Price

$32.04

Market Cap

521.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
RGR
Founded
2019
1949
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Ordnance And Accessories
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
521.9M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
MLYS
RGR
Price
$37.58
$32.04
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$47.33
N/A
AVG Volume (30 Days)
1.6M
468.4K
Earning Date
02-11-2026
11-05-2025
Dividend Yield
N/A
2.19%
EPS Growth
N/A
N/A
EPS
N/A
0.16
Revenue
N/A
$540,770,000.00
Revenue This Year
N/A
$0.73
Revenue Next Year
N/A
$2.27
P/E Ratio
N/A
$202.34
Revenue Growth
N/A
3.90
52 Week Low
$8.24
$28.33
52 Week High
$47.65
$48.21

Technical Indicators

Market Signals
Indicator
MLYS
RGR
Relative Strength Index (RSI) 44.79 44.83
Support Level $36.01 $30.93
Resistance Level $38.40 $33.72
Average True Range (ATR) 1.79 1.24
MACD -0.05 0.33
Stochastic Oscillator 37.98 44.48

Price Performance

Historical Comparison
MLYS
RGR

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About RGR Sturm Ruger & Company Inc.

Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.

Share on Social Networks: